Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life, in biopharmaceuticals, developing therapies to treat cancer, multiple sclerosis, and endocrine conditions.

In endocrinology, Merck has established treatments in diabetes and growth hormone replacement, treating thousands of patients in the UK.  With growth hormone therapy we are enhancing our digital tools in line with NHS Digital transformation plan and are committed to meeting patients’ and healthcare professionals’ evolving needs.

Merck has launched new systems and apps which work in conjunction or alongside the easypod™ injection device, to support both the patient and healthcare professional get the best from Merck therapies.    New systems include: a new easypod™ Connect platform, growlink™ app and easypod™ Augment Reality (AR) App.  These digital solutions are integrated to the MySupport patient support programme, available for device training and nurse-led support. 

Document code: UI-SAI-00126                                  Date of preparation: September 2021